TACTILE SYSTEMS TECHNOLOGY INC
No SEC Form 4 filings for $TCMD in the last 30 days.
See all $TCMD insider activity →Tactile Systems Technology (TCMD) will release Q3 2026 results after market close on Nov 2, 2026, followed by a conference call at 5 p.m. ET. The company develops at-home therapies for chronic disorders. Investors can join the call or access a replay and webcast.
Tactile Systems Technology (TCMD) reported Q2 2026 revenue of $85.7M, up 9% Y/Y, driven by lymphedema revenue of $73.6M (+12%). Airway clearance revenue fell 7% to $12.1M due to distributor inventory dynamics. Gross margin was 76.3%. Adjusted EBITDA rose to $11.4M (+49%). FY2026 revenue guidance was set at $360M-$366M and EBITDA at $49M-$51M.
Tactile Systems Technology reported Q2 2026 results: lymphedema revenue rose 12% YoY on Flexitouch adoption, while airway clearance revenue fell 7% as large DME partners paused orders amid elevated inventory. Gross margin increased 180 bps to 76.3%. Full-year 2026 revenue guidance was raised to $360m-$366m; MyoSleeve launch and LymphaTech FDA submission are ongoing.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TCMD (TACTILE SYSTEMS TECHNOLOGY INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TCMD coverage spans earnings, financial news and insider activity.
The earnings announcement may drive short-term volatility as investors position ahead of the results.
Guidance update plus segment-specific headwinds (airway clearance inventory) and Medicare prior authorization moderation create a near-term demand and margin narrative.
Guidance update plus timing commentary around Medicare prior authorization and DME inventory should drive near-term estimate revisions and trading around Q3 sequential growth expectations.
This is a routine insider sale disclosure with no stated 10b5-1 plan, which can modestly affect near-term sentiment but is not a fundamental catalyst by itself.
The 8-K provides fresh earnings datapoints plus a guidance update, with a clear near-term demand timing risk tied to AffloVest inventory digestion.
AlphAI scores every news story that mentions TCMD with an AI model for sentiment and relevance, and aggregates insider trades from TACTILE SYSTEMS TECHNOLOGY INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Tactile Systems Technology (TCMD) will release Q3 2026 results after market close on Nov 2, 2026, followed by a conference call at 5 p.m. ET. The company develops at-home therapies for chronic disorders. Investors can join the call or access a replay and webcast.
1 min readTactile Systems Technology (TCMD) reported Q2 2026 revenue of $85.7M, up 9% Y/Y, driven by lymphedema revenue of $73.6M (+12%). Airway clearance revenue fell 7% to $12.1M due to distributor inventory dynamics. Gross margin was 76.3%. Adjusted EBITDA rose to $11.4M (+49%). FY2026 revenue guidance was set at $360M-$366M and EBITDA at $49M-$51M.
7 min readTactile Systems Technology reported Q2 2026 results: lymphedema revenue rose 12% YoY on Flexitouch adoption, while airway clearance revenue fell 7% as large DME partners paused orders amid elevated inventory. Gross margin increased 180 bps to 76.3%. Full-year 2026 revenue guidance was raised to $360m-$366m; MyoSleeve launch and LymphaTech FDA submission are ongoing.
7 min readDodd Sheri Louise (Chief Executive Officer) sold 10,978 shares of TACTILE SYSTEMS TECHNOLOGY INC (TCMD) at $29.44 ($0.32M total) on 2026-08-10.
2 min readTACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with ch
6 min readTactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.
4 min readBTIG Research has reiterated a "Buy" rating for Tactile Systems Technology (NASDAQ:TCMD) and maintained a $40 price target, suggesting a potential 61% upside. Other analysts also have a "Moderate Buy" consensus with an average target of $38.60. The company recently reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations, with shares trading around $24.84.
2 min readTactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.60. Despite missing EPS estimates, the company exceeded revenue expectations in its latest quarter. Insider selling was observed, but institutional ownership remains high, with several major funds increasing or establishing positions.
3 min readTactile Systems Technology (NASDAQ:TCMD) VP Kristie Burns sold 5,139 shares of company stock for $148,260.15 on January 2nd, reducing her stake by 6.63%. This transaction follows an earnings beat for the company, which reported EPS of $0.36 against an expected $0.16 and revenue of $85.76 million versus $79.31 million projected. Shares traded up 1.2% to $30.50, and institutional investors own 83.43% of the stock.
2 min readHere is how Tactile Systems Technology (TCMD) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
3 min read
